Gan & Lee Pharmaceutical

Gan Lee Pharmaceuticals, headquartered in Beijing, is a leading Chinese pharmaceutical company specializing in the development, production, and commercialization of insulin analogs and medical devices. Founded in 1998, Gan Lee has grown to employ over 4,000 people globally and operates an industrial park spanning approximately 200,000 square meters. The company is renowned for developing the first Chinese domestic insulin analog and has a series of insulin products approved in China. Gan Lee's market extends internationally, with its products available in countries such as Egypt, Pakistan, and Mexico. The company has also established subsidiaries in New Jersey, USA, and Hong Kong, China, to bolster its global business development and production capabilities. Gan Lee serves a diverse clientele, including healthcare providers and patients requiring insulin therapy. The company operates within the biopharmaceutical market, focusing on innovative solutions for diabetes management. Gan Lee's business model revolves around research and development, manufacturing, and sales of its pharmaceutical products, generating revenue through both domestic and international markets. The company's commitment to innovation and quality has earned it numerous accolades, including the 2021 Outstanding Industrial Contribution Award for China Listed Companies and the 2021 Evergreen Award for Innovative Pharmaceutical Company of the Year.

Keywords: insulin analogs, medical devices, biopharmaceutical, diabetes management, global expansion, innovation, healthcare, manufacturing, research and development, pharmaceutical industry.